宫颈腺癌HER-2/neu和P53的表达及其临床病理学意义

目的:研究宫颈腺癌HER-2/neu和P53蛋白的表达及其临床病理意义,探讨这些生物标记在临床治疗选择中的作用。方法:应用EnVision 免疫组织化学方法,对HER-2/neu、P53以及雌激素受体(ER)和孕激素受体(PR)蛋白在76例宫颈腺癌中的表达情况进行观察,并对其与宫颈腺癌临床病理特征的关系进行统计学分析。结果:HER-2/neu、P53、ER和PR蛋白在宫颈腺癌中的阳性表达率分别为18·4%(14/76)、36·8%(28/76)、27·6%(21/76)和25·0%(19/76)。HER-2/neu的过度表达与手术分期、肿瘤大小、组织学类型和分级及淋巴血管浸润等临床病理学特征无明显相关性;P53蛋白在高、中分化组(G1 G2)的阳性表达率显著低于低分化组(G3)(χ2=8·732,P=0·003),在有淋巴血管浸润的宫颈腺癌的表达率明显高于无淋巴血管浸润者(P=0·039);HER-2/neu与P53的过度表达呈正相关(r=0·27,P=0·018)。结论:HER-2/neu和P53蛋白过度表达可作为部分宫颈腺癌浸润和不良预后的良好标记物,对选择有效的治疗方案有重要意义。

Expression of HER-2/neu and P53 in cervical adenocarcinoma and its clinicopathological significance

Objective:To investigate overexpression of HER-2/neu and P53 in cervical adenocarcinoma, and to explore the possibility of using these biomarkers in treatment of cervical adenocarcinoma. Methods:Overexpression of the HER-2/neu, P53, estrogen receptor (ER) and progesterone receptor (PR) protein were studied by EnVision plus immunohistochemistry in paraffin-embedded tumor tissues from 76 patients with cervical adenocarcinoma, and then the correlations between these biomarkers overexpression and clinicopathological characteristics were analyzed statistically. Results:HER-2/neu, P53, ER and PR were found to be with the positive rates of 18.4% (14/76), 36.8%(28/76), 27.6% ( 21/76) and 25%(19/76) respectively in cervical adenocarcinoma. HER-2/neu expression did not correlated with clinicopathologic features of the tumors. The expression rate of P53 was higher in poor-differentiated carcinomas, especially in carcinomas with lymphovascular invasion, than in well-differentiated and medium-differentiated carcinomas. There was a significantly positive correlation between P53 and HER-2/neu (r=0.27,P=0.018). Conclusion:The overexpression of HER-2/neu and P53 was found in a small number of cervical adenocarcinomas, and these two biomarkers may be helpful in predicting biologic behaviors and planning treatment in cervical adenocarcinoma patients.